Bolt Biotherapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Bolt Biotherapeutics Free Cash Flow (FCF) History (BOLT)
Bolt Biotherapeutics reported −$39.9M in free cash flow for fiscal 2025, an increase of $21.4M from the previous fiscal year, with a free cash flow margin of −518.80%.
View full Bolt Biotherapeutics company overviewBolt Biotherapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$39.9M | $21.4M | — | −518.80% |
| 2024 | 2024-12-31 | −$61.3M | $8.4M | — | −797.53% |
| 2023 | 2023-12-31 | −$69.7M | $8.7M | — | −885.36% |
| 2022 | 2022-12-31 | −$78.5M | −$19.1M | — | −1369.47% |
| 2021 | 2021-12-31 | −$59.4M | −$8.8M | — | −4714.60% |
| 2020 | 2020-12-31 | −$50.6M | — | — | −21891.77% |
Bolt Biotherapeutics quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q3.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$9.8M | $6.9M | — | −452.01% |
| Q4 2024 | 2024-12-31 | −$14.4M | −$159,000 | — | — |
| Q3 2024 | 2024-09-30 | −$14.0M | $2.9M | — | −1227.61% |
| Q2 2024 | 2024-06-30 | −$16.1M | −$998,000 | — | −1266.04% |
| Q1 2024 | 2024-03-31 | −$16.8M | $6.7M | — | −317.61% |
| Q4 2023 | 2023-12-31 | −$14.3M | $3.9M | — | −683.15% |
| Q3 2023 | 2023-09-30 | −$16.9M | −$2.7M | — | −669.07% |
| Q2 2023 | 2023-06-30 | −$15.1M | $6.1M | — | −1056.80% |
| Q1 2023 | 2023-03-31 | −$23.4M | $1.5M | — | −1281.60% |
| Q4 2022 | 2022-12-31 | −$18.1M | $220,000 | — | −1285.33% |
| Q3 2022 | 2022-09-30 | −$14.2M | $5.6M | — | −671.69% |
| Q2 2022 | 2022-06-30 | −$21.2M | −$16.5M | — | −1523.04% |
| Q1 2022 | 2022-03-31 | −$24.9M | −$8.3M | — | −3065.07% |
| Q4 2021 | 2021-12-31 | −$18.4M | −$4.6M | — | — |
| Q3 2021 | 2021-09-30 | −$19.7M | −$6.1M | — | −2625.27% |
| Q2 2021 | 2021-06-30 | −$4.7M | $8.4M | — | — |
| Q1 2021 | 2021-03-31 | −$16.6M | −$6.6M | — | — |
| Q4 2020 | 2020-12-31 | −$13.8M | — | — | — |
| Q3 2020 | 2020-09-30 | −$13.7M | — | — | −20397.01% |
| Q2 2020 | 2020-06-30 | −$13.1M | — | — | −19559.70% |
| Q1 2020 | 2020-03-31 | −$10.0M | — | — | −6104.27% |
Bolt Biotherapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$50.6M to −$39.9M, a net increase of $10.6M. Bolt Biotherapeutics's latest reported quarter, Q3 2025, generated −$9.8M in free cash flow, an increase of $6.9M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Bolt Biotherapeutics filings at SEC.gov ↗